Published mark
Alto Neuroscience, Inc.
NYSE: ANRO. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:966e52c8-6b93-4ce6-91cf-fdc60f460f3c
- SEC CIK
- 0001999480
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 17, 2026
- Newest evidence
- Mar 26, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Amit Etkin, M.D., Ph.D.President, Chief Executive Officer, and Chair of the Board
- Chair
- Amit Etkin, M.D., Ph.D.Lead independent: Christopher Nixon Cox
- Independent
- Not published7 directors published
- Published claims
- 352 distinct sources
- Evidence records
- 40 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 4 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Adam Savitz, M.D., Ph.D. seat on Alto Neuroscience, Inc., effective 2026-03-26.
EffectiveEffective Mar 26, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| General Counsel and Chief Administrative Officer | Erin R. McQuade | Mar 2026 | current | Source reportedE3 |
| Chief Medical Officer | Adam Savitz, M.D., Ph.D. | Not captured | unknown | Source reportedE2 |
| President, Chief Executive Officer, and Chair of the Board | Amit Etkin, M.D., Ph.D. | Not captured | unknown | Source reportedE2 |
| Chief Operating Officer | Michael Hanley | Not captured | unknown | Source reportedE2 |
| Chief Financial Officer and Chief Business Officer | Nicholas Smith | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence7 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Adam Savitz, M.D., Ph.D. | Independence not published | 2026 | None published | Source reportedE3 |
| Andrew Dreyfus | Independence not published | 2023 | Audit CommitteeCompensation and Management Development CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Gwill York | Independence not published | 2021 | Audit CommitteeCompensation and Management Development CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Husseini Manji | Independence not published | 2024 | Audit CommitteeCompensation and Management Development CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Michael Hanley | Independence not published | 2026 | None published | Source reportedE3 |
| Nicholas Smith | Independence not published | 2026 | None published | Source reportedE3 |
| Raymond Sanchez | Independence not published | 2025 | Audit CommitteeCompensation and Management Development CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Amit Etkin, M.D., Ph.D. | Not independentChair | Not published | Chief Executive Officer, and Chair of the Board | Source reportedE2 |
| Christopher Nixon Cox | IndependentLead Independent | Not published | None published | Source reportedE2 |
| Husseini Manji, M.D. | Independence not published | Not published | None published | Source reportedE2 |
| Raymond Sanchez, M.D. | Independence not published | Not published | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit Committee | Not published | Andrew Dreyfus, Gwill York, Husseini Manji, Raymond Sanchez | Not described in the published record |
| Chief Executive Officer, and Chair of the Board | Not published | Amit Etkin, M.D., Ph.D. | Not described in the published record |
| Compensation and Management Development Committee | Not published | Andrew Dreyfus, Gwill York, Husseini Manji, Raymond Sanchez | Not described in the published record |
| Nominating and Corporate Governance Committee | Not published | Andrew Dreyfus, Gwill York, Husseini Manji, Raymond Sanchez | Not described in the published record |
Committee RecordAudit Committee: Chair not stated; Members Andrew Dreyfus; Gwill York; Husseini Manji; Raymond Sanchez
Committee AppointmentAndrew Dreyfus: member, Audit Committee
Committee AppointmentGwill York: member, Audit Committee
Committee AppointmentHusseini Manji: member, Audit Committee
Committee AppointmentRaymond Sanchez: member, Audit Committee
Committee RecordCompensation and Management Development Committee: Chair not stated; Members Andrew Dreyfus; Gwill York; Husseini Manji; Raymond Sanchez
Committee AppointmentAndrew Dreyfus: member, Compensation and Management Development Committee
Committee AppointmentGwill York: member, Compensation and Management Development Committee
Committee AppointmentHusseini Manji: member, Compensation and Management Development Committee
Committee AppointmentRaymond Sanchez: member, Compensation and Management Development Committee
Committee RecordNominating and Corporate Governance Committee: Chair not stated; Members Andrew Dreyfus; Gwill York; Husseini Manji; Raymond Sanchez
Committee AppointmentAndrew Dreyfus: member, Nominating and Corporate Governance Committee
Committee AppointmentGwill York: member, Nominating and Corporate Governance Committee
Committee AppointmentHusseini Manji: member, Nominating and Corporate Governance Committee
Committee AppointmentRaymond Sanchez: member, Nominating and Corporate Governance Committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerAmit Etkin, M.D., Ph.D., President, Chief Executive Officer, and Chair of the Board
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingANRO (NYSE)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameAlto Neuroscience, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Erin R. McQuadeGeneral Counsel and Chief Administrative Officercompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:18
- Adam Savitz, M.D., Ph.D.Chief Medical Officer; Directorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:16, company:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:6
- Amit Etkin, M.D., Ph.D.President, Chief Executive Officer, and Chair of the Boardcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:17, company:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:5
- Michael HanleyChief Operating Officer; Directorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:19, company:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:12
- Nicholas SmithChief Financial Officer and Chief Business Officer; Directorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:20, company:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:13
- Andrew DreyfusDirectorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:7
- Gwill YorkDirectorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:9
- Husseini ManjiDirectorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:10
- Raymond SanchezDirectorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:14
- Christopher Nixon CoxLead Independent Directorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:8
- Husseini Manji, M.D.Directorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:11
- Raymond Sanchez, M.D.Directorcompany:966e52c8-6b93-4ce6-91cf-fdc60f460f3c:leadership_role:15
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 4 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 17, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Mar 26, 2026. Retrieved Sep 5, 2026. Cited by 8 Claims.
- E3sec proxy. Published Mar 26, 2026. Retrieved Sep 2, 2026. Cited by 8 Claims.
- E4governance_people_committees. sec proxy. Cited by 15 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 17, 2026- Adam Savitz, M.D., Ph.D. seat on Alto Neuroscience, Inc., effective 2026-03-26.
- Michael Hanley seat on Alto Neuroscience, Inc., effective 2026-03-26.
- Nicholas Smith seat on Alto Neuroscience, Inc., effective 2026-03-26.
- Erin R. McQuade executive of Alto Neuroscience, Inc., effective 2026-03-26.
- Raymond Sanchez seat on Alto Neuroscience, Inc., effective 2025-01-01.
- Husseini Manji seat on Alto Neuroscience, Inc., effective 2024-01-01.
- Andrew Dreyfus seat on Alto Neuroscience, Inc., effective 2023-01-01.
- Gwill York seat on Alto Neuroscience, Inc., effective 2021-01-01.